Clinical research company Medpace Holdings (NASDAQ: MEDP) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 26.5% year on year to $706.6 million. The company expects the full year’s revenue to be around $2.81 billion, close to analysts’ estimates. Its GAAP profit of $4.28 per share was 10.2% above analysts’ consensus estimates.

Is now the time to buy MEDP? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Medpace’s first quarter was marked by substantial year-over-year revenue growth, but management’s discussion centered on increased project cancellations and a lower book-to-bill ratio. CEO August James Troendle called out cancellations reaching their highest point in over a year, attributing the trend to “random items you would expect: product performance, reprioritization, etc.”, with oncology and cardiovascular areas being most affected. Although win rates and initial award notifications were strong, Troendle acknowledged that gross bookings were at the low end, combining with cancellations to pressure backlog and limit net new business growth.

Looking ahead, management maintained its full-year guidance but acknowledged that future performance will depend on reducing cancellation rates or improving gross awards. Troendle emphasized ongoing initiatives to expand the pipeline and increase win rates, stating, “We are very focused on this and see opportunities to expand both our pipeline and win rate to combat higher cancellations and get back to the growth rate we want.” CFO Kevin M. Brady cautioned that while the current modeling supports guidance, persistent cancellations could impact revenue visibility and sequential growth in the coming quarters.

Key Insights from Management’s Remarks

Management attributed the quarter’s results to elevated cancellations in key therapeutic areas and softer gross bookings, despite solid execution in initial awards and win rates.

• Elevated project cancellations: Cancellations were notably high, especially in oncology and cardiovascular studies. Troendle clarified that these were not driven by macroeconomic or funding pressures, but by typical project-specific reasons such as product performance and sponsor reprioritization.

• Softer gross bookings: Gross new business awards were at the low end of expectations, which, combined with cancellations, reduced the net book-to-bill ratio to 0.88. Management indicated this reflected a mix of weaker new opportunity flow and lingering effects from past pre-backlog cancellations.

• Metabolic and GLP-1 stability: Despite investor concerns over volatility in metabolic and GLP-1 (a class of drugs for obesity and diabetes) trials, Troendle noted that metabolic work remains “pretty safe” for Medpace. GLP-1-related cancellations were not elevated, and metabolic trials historically show lower cancellation rates than other areas.

• Pipeline and pre-backlog growth: While net bookings lagged, management pointed to growth in the pre-backlog pool—work authorized but not yet started. This suggests potential future conversion into revenue, although timing remains uncertain due to inherent project risks in clinical research.

• Leadership transition: The quarter marked the retirement of President Jesse J. Geiger after eighteen and a half years. Troendle will reassume the role of President, and leadership emphasized depth in the broader management team to ensure continuity.

Drivers of Future Performance

Medpace’s outlook for the rest of the year hinges on stabilizing cancellations and converting its growing pre-backlog into revenue, while managing margin discipline amid ongoing investment.

• Cancellation rate remains a risk: Management acknowledged that persistently high cancellations could continue to pressure net bookings and revenue visibility, especially if gross new awards do not rebound. Troendle highlighted the need for “either cancellations to abate or gross awards to improve” to support sequential growth.

• Pipeline expansion and win rate focus: The company is undertaking initiatives to improve win rates and expand its business development pipeline. Troendle expects these measures to yield results over the next few quarters, aiming to offset cancellation headwinds and return to a more typical growth trajectory.

• Margin management amid hiring and investment: Despite softness in bookings, Medpace continued to hire, signaling confidence in future growth. CFO Brady noted that improved employee retention and controlled SG&A (selling, general, and administrative) costs are expected to help sustain operating margins, even as investments in AI and operational efficiencies are not anticipated to provide net benefits in the near term.

Catalysts in Upcoming Quarters

As we look forward, the StockStory team will monitor (1) trends in project cancellations, particularly in oncology and cardiovascular, to assess whether rates moderate, (2) evidence of higher gross bookings or improved win rates stemming from business development initiatives, and (3) the pace of pre-backlog conversion into revenue. Management’s ability to maintain operating margins while investing in operational efficiencies and talent will also be a key marker of execution.

Medpace currently trades at $394.82, down from $508.46 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

High Quality Stocks for All Market Conditions

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.